Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase....

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Immunol Immunother
Asıl Yazarlar: Coleman, Hannah N., Greenfield, William W., Stratton, Shawna L., Vaughn, Rita, Kieber, Alexander, Moerman-Herzog, Andrea M., Spencer, Horace J., Hitt, Wilbur. C., Quick, Charles Matthew, Hutchins, Laura F., Mackintosh, Samuel G., Edmondson, Ricky D., Erickson, Stephen W., Nakagawa, Mayumi
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841729/
https://ncbi.nlm.nih.gov/pubmed/26980480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1821-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller